BioSpace News Archive

Feb. 20, 2020 13:00 UTC Lineage Cell Therapeutics to Present at Biocom’s 10 th Annual Global Life Sciences Partnering Conference CARLSBAD, Calif.--( BUSINESS WIRE )-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at Biocom’s 10 th Annual Global Life Sciences Partnering Conference o

Feb. 20, 2020 13:00 UTC Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol ® Cyclo™ for the Treatment of Niemann-Pick Disease Type C GAINESVILLE, Fla.--( BUSINESS WIRE )-- Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has completed patient enrollment in its Phase I/

Feb. 20, 2020 13:00 UTC Alnylam to Webcast Presentation at 9 th Annual SVB Leerink Global Healthcare Conference CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 9 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 27, 2020 at 9:30 am ET at the Lotte New York Palace Hotel in New York City. A live audio webcast

Provides funds to evaluate the mechanistic antiviral activity of WH602 Novan to progress IND-enabling toxicology and pharmacology studies for WH602 Grant is additive to $223,000 Phase 1 NIH grant received in August 2019 Women’s health initiative focused on potential HPV related onco-virus therapeutics MORRISVILLE, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has received approximately $1.0 million fu

Results Include More Members, More In-Network Physicians, and More Local Jobs

Stock market gains and dealmaking activity in Q4 clinched the biopharma sector’s strong performance in 2019 – a stark reversal of the declines seen in the final months of 2018.

Calidi Biotherapeutics, Inc. (“Calidi”), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, Heehyoung Lee, Managing Partner at LumeBio, to its board of directors

Delta Dental released new findings from its Original Tooth Fairy Poll® that show a 30-cent increase in the Tooth Fairy’s average cash gift for a total of $4.03 per tooth.

Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin’s president and chief executive officer, is scheduled to present general company updates at two upcoming investor conferences

i:X Platform’s Precise Wound Measurement, along with Fluorescence Imaging, for More Accurate Detection and Ongoing Documentation of Wounds